Wed, Jul 30, 2014, 4:17 AM EDT - U.S. Markets open in 5 hrs 13 mins


% | $
Click the to save as a favorite.

ImmunoGen, Inc. Message Board

chinesehamsters 7 posts  |  Last Activity: Jul 28, 2014 3:53 PM Member since: Sep 24, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Earnings expectations?

    by afro_bro_bro Jul 28, 2014 1:23 PM
    chinesehamsters chinesehamsters Jul 28, 2014 3:53 PM Flag

    I keep seeing that comment here, that Kadcyla is dissapointing because Perjeta sales are so much better. Currently Perjeta is approved for two indications in combination use with Herceptin. Kadcyla is currently approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body. So it should not be a big surprise that Perjeta is currently outselling Kadcyla, just due to the approved indications and thus what oncologists can prescribe within the label.

    If you go to clinical yo will see over 40 trials for Kadcyla. The big trial (MARIANNE) ongoing is in 1st line MBC, and that trial has one arm with Kadcyla plus Perjeta. This is the indication that will put Kadcyla on the map and open up earnings considerably. We should see some data in 2014, but the trial is not scheduled to end until April 2016. So just sit back and wait.

    Chinese Hamsters

  • Reply to

    I'm feeling a good vibe somehow

    by slumdawg2011 Jul 18, 2014 12:34 PM
    chinesehamsters chinesehamsters Jul 18, 2014 3:09 PM Flag

    I don't have the confidence in the IMGN management to monetize the full potential of Kadcyla sales. They may monetize on a peak sales of $5 billion rather than the $9 billion that will eventually materialize.

    Chinese Hamsters

  • Reply to

    Seriously, #$%$?

    by chinesehamsters Jul 16, 2014 2:46 PM
    chinesehamsters chinesehamsters Jul 16, 2014 4:48 PM Flag

    A press release noting the granting of orphan drug status for a molecule would not be material if they were in talks of being bought out. I am not buying that for an excuse. I hope they do get bought out, anywhere between $15 - $20 a share. That way I don't have to watch their miserable performance any longer.

    Chinese Hamsters

  • chinesehamsters by chinesehamsters Jul 16, 2014 2:46 PM Flag

    The drug given orphan drug status is most definately their folate targeting ADC 853, which is wholly owned by Immunogen. Is it that much effort to put out your own press release? At this point even this board of directors has to be getting tired of this #$%$. Junius should just resign or kill himself. I never thought this company would still be floundering in 2014 with such an impressive technology at their disposal. I wonder what those 10 or so biz development people do with their time. This is just hard to watch anymore.

    Chinese Hamsters

  • Reply to

    IMGN started at BUY

    by bioimmunomabman Apr 16, 2014 9:28 AM
    chinesehamsters chinesehamsters Apr 16, 2014 3:26 PM Flag

    Finally an analyst with a calculator did the math. They are still a bit short on their forecast of Kadcyla sales however. It will approach closer to $9 billion than the $7 they are predicting. I have been saying that for the last two years. Kadcyla is why I bought this stock and stick with it. Anything else that comes out of the pipeline is just gravy.

    Chinese Hamsters

  • chinesehamsters chinesehamsters Mar 4, 2014 11:43 AM Flag

    IDEC did develop Rituxan, and Genentech inked a deal early on (1995) to take on commercial manufacturing in exchange for a royalty arrangement. The royalty in retrospect was pretty small, but for IDEC at the time a piece of something was better than nothing at all. Then Roche of course owned the majority share of of Genentech (late just bought them), thus Rituxan sales globally are not reflected in their earnings.

    Thus my speculation that Roche might be thinking about buying Immunogen if they come up with a potential Rituxan replacement. As I said earlier, IMGN 529 is still in a very early stage of development, so maybe wishful thinking.

    Chinese Hamsters

  • chinesehamsters chinesehamsters Mar 3, 2014 5:36 PM Flag

    I think Roche is more likely to buy out Immunogen than Seattle Genetics for a couple of reasons. First is that they would just save themselves the trouble of paying the royalty stream to Immunogen on Kadcyla for the next 18 or so years. Second, Immunogen actually has another wholly owned ADCC that gets little mention, IMGN 529. This one is in early clinical testing, but the primary indication is non-Hodgkins B cell lymphoma. Roche has another huge blockbuster drug called Rituxan, which is also going off patent soon. This might be a way of keeping that revenue in-house. I am not aware of what Roche is doing to preserve that market once Rituxan goes off patent. IMGN 529 is not a timely solution for that however, but I do not know of a relevant biosimilar that is in the works by anyone either. TEVA was but squashed their program due to concerns about return on investment.

    Chinese Hamsters

10.95+0.42(+3.99%)Jul 29 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.